Roger Davies

Roger Davies joined Aptose in 2021 as Vice-President of Operations. He has over 30 years of experience in the pharmaceutical industry, in positions of increasing responsibility in both CROs and pharmaceutical companies. Mr. Davies started his clinical research career at a CRO, developing and managing health-care product studies, Phase I and II studies in healthy volunteers and patients, and studies that led to EU-wide approval of a polyvalent immunoglobulin for treatment of primary immune deficiency (PID) and immune thrombocytopenia (ITP). Later, Mr. Davies continued his career in the US, both at major CROs (IQVIA, Syneos, and ICON), where he was responsible for project management teams and large, complex, global Phase III studies, and at small and large biotechnology companies (Lexicon Pharmaceuticals, Intercept Pharmaceuticals, Celgene, Novartis). During this time, Mr. Davies focused on oncology for more than 10 contiguous years, covering both solid and hematological tumors, and for the last five years also gained expertise in metabolic diseases, including Type 1 Diabetes (T1D) and non-alcoholic steatohepatitis (NASH). Mr. Davies’ research passion is oncology, and he is pleased to be involved in this therapeutic area again at Aptose. Mr. Davies gained a degree in Physiology from the University of Newcastle-upon-Tyne, England, and a Master of Philosophy degree (M.Phil.) in physiology from the University of Edinburgh, Scotland.